Track topics on Twitter Track topics that are important to you
Tumor mutational burden (TMB) was not significantly associated with the efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy when used as a first-line treatment for metastatic nonsquamous non–small-cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) held in Barcelona.
Original Article: Is Tumor Mutational Burden a Useful Predictor of NSCLC Therapy Efficacy?NEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...